JP2018536152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536152A5 JP2018536152A5 JP2018517730A JP2018517730A JP2018536152A5 JP 2018536152 A5 JP2018536152 A5 JP 2018536152A5 JP 2018517730 A JP2018517730 A JP 2018517730A JP 2018517730 A JP2018517730 A JP 2018517730A JP 2018536152 A5 JP2018536152 A5 JP 2018536152A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- mcp
- mmr
- ptsd
- normal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 39
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 30
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims 22
- 101710112613 C-C motif chemokine 13 Proteins 0.000 claims 22
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 20
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 20
- 208000020401 Depressive disease Diseases 0.000 claims 11
- 210000004369 blood Anatomy 0.000 claims 11
- 239000008280 blood Substances 0.000 claims 11
- 239000003550 marker Substances 0.000 claims 11
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 10
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 10
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 9
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 9
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 3
- 229960001653 citalopram Drugs 0.000 claims 3
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims 3
- 229960005217 dapoxetine Drugs 0.000 claims 3
- 229960004341 escitalopram Drugs 0.000 claims 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 3
- 229960002464 fluoxetine Drugs 0.000 claims 3
- 229960004038 fluvoxamine Drugs 0.000 claims 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 3
- -1 indalpin Chemical compound 0.000 claims 3
- 229960002296 paroxetine Drugs 0.000 claims 3
- 229960002073 sertraline Drugs 0.000 claims 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 230000002250 progressing effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000001541 thymus gland Anatomy 0.000 claims 2
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 claims 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 claims 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239004P | 2015-10-08 | 2015-10-08 | |
| US62/239,004 | 2015-10-08 | ||
| PCT/US2016/055675 WO2017062568A1 (en) | 2015-10-08 | 2016-10-06 | Biomarkers for diagnosing post traumatic stress disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536152A JP2018536152A (ja) | 2018-12-06 |
| JP2018536152A5 true JP2018536152A5 (show.php) | 2019-11-14 |
Family
ID=58488666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517730A Pending JP2018536152A (ja) | 2015-10-08 | 2016-10-06 | 心的外傷後ストレス障害を診断するためのバイオマーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11085934B2 (show.php) |
| EP (1) | EP3359969A4 (show.php) |
| JP (1) | JP2018536152A (show.php) |
| AU (1) | AU2016334027A1 (show.php) |
| CA (1) | CA2998533A1 (show.php) |
| WO (1) | WO2017062568A1 (show.php) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11529054B2 (en) * | 2018-07-25 | 2022-12-20 | The Charles Stark Draper Laboratory, Inc. | Method and system for post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) diagnosis using magnetic resonance spectroscopy |
| WO2025154785A1 (ja) * | 2024-01-18 | 2025-07-24 | 国立研究開発法人産業技術総合研究所 | 心的外傷後ストレス障害（ｐｔｓｄ）または急性ストレス障害（ａｓｄ）の客観的評価方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2642706C (en) * | 2006-02-17 | 2017-08-01 | Atsuo Sekiyama | Biological load indicator and method of measuring biological load |
| NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN103959067B (zh) | 2011-09-14 | 2018-04-24 | 促进军事医学的亨利·M·杰克逊基金会公司 | 用于检测和监测用于创伤后应激障碍（ptsd）的诊断生物标志物以及用于区分自杀式与非自杀式障碍的试剂盒 |
| WO2016057775A1 (en) | 2014-10-08 | 2016-04-14 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Biomarkers for diagnosing post traumatic stress disorder |
-
2016
- 2016-10-06 WO PCT/US2016/055675 patent/WO2017062568A1/en not_active Ceased
- 2016-10-06 EP EP16854290.0A patent/EP3359969A4/en not_active Withdrawn
- 2016-10-06 JP JP2018517730A patent/JP2018536152A/ja active Pending
- 2016-10-06 CA CA2998533A patent/CA2998533A1/en not_active Abandoned
- 2016-10-06 US US15/759,507 patent/US11085934B2/en not_active Expired - Fee Related
- 2016-10-06 AU AU2016334027A patent/AU2016334027A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020239715B2 (en) | Personalized medicine approach for treating cognitive loss | |
| Bekris et al. | Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease | |
| JP6430413B2 (ja) | アルツハイマー病の診断のための方法と組成物 | |
| JP2014519018A5 (show.php) | ||
| Almond et al. | Obesity dysregulates the pulmonary antiviral immune response | |
| Franciosi et al. | Susceptibility to COPD: differential proteomic profiling after acute smoking | |
| JP2008537474A5 (show.php) | ||
| Breunis et al. | Vascular endothelial growth factor gene haplotypes in Kawasaki disease | |
| Coudroy et al. | Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis | |
| JP2016118568A5 (show.php) | ||
| Ma et al. | Development of a Novel Urine Alzheimer‐Associated Neuronal Thread Protein ELISA Kit and Its Potential Use in the Diagnosis of Alzheimer's Disease | |
| JP2017505897A5 (show.php) | ||
| Pastori et al. | Cardiorenal syndrome type 1: a defective regulation of monocyte apoptosis induced by proinflammatory and proapoptotic factors | |
| JP2007508527A5 (show.php) | ||
| Petrozziello et al. | Lipocalin‐2 is increased in amyotrophic lateral sclerosis | |
| Arslan et al. | Importance of endothelial dysfunction biomarkers in patients with Crimean‐Congo hemorrhagic fever | |
| JP6779200B2 (ja) | 川崎病の診断及び治療 | |
| JP2016526167A5 (show.php) | ||
| JP2018536152A5 (show.php) | ||
| Cay et al. | Gene network analysis for identification of microRNA biomarkers for asthma | |
| Wang et al. | CXCL5 is associated with the increased risk of coronary artery disease | |
| Lima et al. | Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression | |
| Hamlin et al. | Challenges and opportunities in long COVID research | |
| JP2017524933A5 (show.php) | ||
| Laudanski et al. | Maternal plasma and amniotic fluid chemokines screening in fetal Down syndrome |